Plus Therapeutics Files 8-K, Updates Corporate Information
Ticker: PSTV · Form: 8-K · Filed: Nov 14, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Nov 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
TL;DR
Plus Therapeutics filed an 8-K updating their address and former names.
AI Summary
On November 14, 2024, PLUS THERAPEUTICS, INC. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4200 Marathon Blvd., Suite 200, Austin, Texas, 78756. The report also lists the company's former names, including CYTORI THERAPEUTICS, INC. and MACROPORE INC.
Why It Matters
This filing provides updated corporate information and addresses for Plus Therapeutics, Inc., which is important for investors and stakeholders to ensure they have the correct contact and location details for the company.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain information about significant financial events, risks, or operational changes.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- 4200 Marathon Blvd., Suite 200, Austin, Texas, 78756 (location) — Principal Executive Offices
- CYTORI THERAPEUTICS, INC. (company) — Former Company Name
- MACROPORE INC (company) — Former Company Name
- November 14, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically detailing the company's principal executive offices and former company names.
What is the current address of Plus Therapeutics, Inc.'s principal executive offices?
The principal executive offices of Plus Therapeutics, Inc. are located at 4200 Marathon Blvd., Suite 200, Austin, Texas, 78756.
When was the earliest event reported in this filing?
The earliest event reported in this filing is dated November 14, 2024.
What were some of the former names of Plus Therapeutics, Inc. mentioned in the filing?
The filing mentions that Plus Therapeutics, Inc. was formerly known as CYTORI THERAPEUTICS, INC. and MACROPORE INC.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-11-14 16:12:40
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share PSTV The Nasdaq Capital M
Filing Documents
- pstv-20241114.htm (8-K) — 43KB
- pstv-ex99_1.htm (EX-99.1) — 301KB
- 0000950170-24-127067.txt ( ) — 480KB
- pstv-20241114.xsd (EX-101.SCH) — 30KB
- pstv-20241114_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 14, 2024, Plus Therapeutics, Inc. (the "Company") reported financial results for the third quarter ended September 30, 2024 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference. The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Announcing Financial Results, dated November 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: November 14, 2024 By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D. President and Chief Executive Officer